Roche app allows access to latest cancer guidelinesRoche has launched an app allowing access to the latest guidelines covering the most common forms of cancer. Share XRoche app allows access to latest cancer guidelineshttps://pharmaphorum.com/news/roche-app-allows-access-to-latest-cancer-guidelines/
Roche sets analysts purring with strong Q3 resultsRoche has beaten market expectations in third quarter results, with new drugs gaining traction and its older medicines Share XRoche sets analysts purring with strong Q3 resultshttps://pharmaphorum.com/news/roche-sets-analysts-purring-with-strong-q3-results/
Roche backs Rituxan with further data in rare skin disease PVRoche’s Rituxan (rituximab) has been on the market for years as a blood cancer drug, and is finally Share XRoche backs Rituxan with further data in rare skin disease PVhttps://pharmaphorum.com/news/roche-backs-rituxan-with-further-data-in-rare-skin-disease-pv/
Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
MHRA says Avastin can be used for AMD despite Bayer, Novartis objectionsThe UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, Share XMHRA says Avastin can be used for AMD despite Bayer, Novartis objectionshttps://pharmaphorum.com/news/mhra-says-avastin-can-be-used-for-amd-despite-bayer-novartis-objections/
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EUBayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share XBayer’s Vitrakvi is first tumour-agnostic drug approved in EUhttps://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
Roche’s Gazyva wins Breakthrough Therapy status for lupus nephritisRoche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, Share XRoche’s Gazyva wins Breakthrough Therapy status for lupus nephritishttps://pharmaphorum.com/news/roches-gazyva-wins-breakthrough-therapy-status-for-lupus-nephritis/
